Management of post-transplant lymphoproliferative disorders

Area of Science:

• Pediatric Hematology/Oncology
• Immunology
• Virology

Background:

• Post-transplant lymphoproliferative disease (PTLD) is a significant complication following hematopoietic stem cell and solid organ transplantation.
• The rising incidence of pediatric transplantation has made PTLD the most prevalent lymphoproliferative disorder in children.
• Epstein-Barr virus (EBV) is implicated in the majority of pediatric PTLD cases.

Purpose of the Study:

• To review the role of Epstein-Barr virus (EBV) in the pathophysiology of PTLD.
• To discuss current and emerging management strategies for PTLD in pediatric transplant recipients.

Main Methods:

• Review of current literature on EBV and PTLD in pediatric transplantation.
• Analysis of the immunological mechanisms underlying EBV-driven lymphoproliferation.
• Evaluation of treatment modalities including immunosuppression reduction, antibody therapy, chemotherapy, and cellular therapies.

Main Results:

• Over 90% of pediatric PTLD cases are associated with EBV.
• Immunosuppression, necessary to prevent graft rejection, impairs T-cell control of EBV, increasing PTLD risk, especially in EBV-seronegative recipients who seroconvert post-transplant.
• Standard treatments include immunosuppression reduction, rituximab, and chemotherapy.

Conclusions:

• EBV is a critical factor in pediatric PTLD pathogenesis.
• Cellular therapies targeting EBV-specific antigens represent a promising future direction for PTLD treatment, potentially supplanting traditional chemotherapy.